GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (LSE:GSK) » Definitions » Cyclically Adjusted Revenue per Share

GSK (LSE:GSK) Cyclically Adjusted Revenue per Share : £8.33 (As of Mar. 2024)


View and export this data going back to 1972. Start your Free Trial

What is GSK Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GSK's adjusted revenue per share for the three months ended in Mar. 2024 was £1.790. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is £8.33 for the trailing ten years ended in Mar. 2024.

During the past 12 months, GSK's average Cyclically Adjusted Revenue Growth Rate was 0.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GSK was 8.90% per year. The lowest was 0.60% per year. And the median was 5.05% per year.

As of today (2024-05-14), GSK's current stock price is £18.10. GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was £8.33. GSK's Cyclically Adjusted PS Ratio of today is 2.17.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.72. The lowest was 1.57. And the median was 2.10.


GSK Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for GSK's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted Revenue per Share Chart

GSK Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.61 7.45 7.67 8.22 8.34

GSK Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.27 8.36 8.38 8.34 8.33

Competitive Comparison of GSK's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PS Ratio falls into.



GSK Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.79/130.0000*130.0000
=1.790

Current CPI (Mar. 2024) = 130.0000.

GSK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.426 99.800 1.858
201409 1.451 100.000 1.886
201412 1.607 99.900 2.091
201503 1.446 99.600 1.887
201506 1.510 100.100 1.961
201509 1.570 100.200 2.037
201512 1.593 100.400 2.063
201603 1.592 100.400 2.061
201606 1.680 101.000 2.162
201609 1.923 101.500 2.463
201612 1.913 102.200 2.433
201703 1.877 102.700 2.376
201706 1.872 103.500 2.351
201709 1.987 104.300 2.477
201712 1.921 105.000 2.378
201803 1.826 105.100 2.259
201806 1.842 105.900 2.261
201809 2.034 106.600 2.480
201812 2.055 107.100 2.494
201903 1.924 107.000 2.338
201906 1.956 107.900 2.357
201909 2.343 108.400 2.810
201912 2.198 108.500 2.634
202003 2.268 108.600 2.715
202006 1.897 108.800 2.267
202009 2.144 109.200 2.552
202012 -0.249 109.400 -0.296
202103 1.841 109.700 2.182
202106 1.446 111.400 1.687
202109 1.635 112.400 1.891
202112 1.742 114.700 1.974
202203 1.768 116.500 1.973
202206 1.364 120.500 1.472
202209 1.915 122.300 2.036
202212 1.803 125.300 1.871
202303 1.702 126.800 1.745
202306 1.403 129.400 1.410
202309 1.981 130.100 1.979
202312 1.954 130.000 1.954
202403 1.790 130.000 1.790

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


GSK  (LSE:GSK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GSK's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=18.10/8.33
=2.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.72. The lowest was 1.57. And the median was 2.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GSK Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK (LSE:GSK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (LSE:GSK) » Definitions » Cyclically Adjusted Revenue per Share
Address
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.